Diabetes, Vol 48, Issue 1 198-202, Copyright © 1999 by American Diabetes Association

ARTICLES

Metformin reduces systemic methylglyoxal levels in type 2 diabetes

PJ Beisswenger, SK Howell, AD Touchette, S Lal and BS Szwergold
Department of Medicine, Dartmouth-Hitchcock Medical Center and Dartmouth Medical School, Lebanon, New Hampshire 03756, USA. paul.j.beisswenger@hitchcock.org

Methylglyoxal (MG) is a reactive alpha-dicarbonyl that is thought to contribute to diabetic complications either as a direct toxin or as a precursor for advanced glycation end products. It is produced primarily from triose phosphates and is detoxified to D-lactate (DL) by the glyoxalase pathway. Because guanidino compounds can block dicarbonyl groups, we have investigated the effects of the diamino biguanide compound metformin and of hyperglycemia on MG and its detoxification products in type 2 diabetes. MG and DL were measured by high-performance liquid chromatography in plasma from 57 subjects with type 2 diabetes. Of these subjects, 27 were treated with diet, sulfonylureas, or insulin (nonmetformin), and 30 were treated with metformin; 28 normal control subjects were also studied. Glycemic control was determined by HbA1c. MG was significantly elevated in diabetic subjects versus the normal control subjects (189.3 +/- 38.7 vs. 123.0 +/- 37 nmol/l, P = 0.0001). MG levels were significantly reduced by high-dosage (1,500-2,500 mg/day) metformin (158.4 +/- 44.2 nmol/l) compared with nonmetformin (189.3 +/- 38.7 nmol/l, P = 0.03) or low-dosage (< or = 1,000 mg/day) metformin (210.98 +/- 51.0 nmol/l, P = 0.001), even though the groups had similar glycemic control. Conversely, DL levels were significantly elevated in both the low- and high-dosage metformin groups relative to the nonmetformin group (13.8 +/- 7.7 and 13.4 +/- 4.6 vs. 10.4 +/- 3.9 micromol/l, P = 0.03 and 0.06, respectively). MG correlated with rising HbA1c levels (R = 0.4, P = 0.03, slope = 13.2) in the nonmetformin subjects but showed no increase with worsening glycemic control in the high-dosage metformin group (R = 0.0004, P = 0.99, slope = 0.02). In conclusion, MG is elevated in diabetes and relates to glycemic control. Metformin reduces MG in a dose-dependent fashion and minimizes the effect of worsening glycemic control on MG levels. To the extent that elevated MG levels lead to their development, metformin treatment may protect against diabetic complications by mechanisms independent of its antihyperglycemic effect.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				G. Cohen, G. Glorieux, P. Thornalley, E. Schepers, N. Meert, J. Jankowski, V. Jankowski, A. Argiles, B. Anderstam, P. Brunet, et al. Review on uraemic toxins III: recommendations for handling uraemic retention solutes in vitro towards a standardized approach for research on uraemia Nephrol. Dial. Transplant., August 27, 2007; (2007) gfm210v1. [Full Text] [PDF]

				A. G. Miller, D. G. Smith, M. Bhat, and R. H. Nagaraj Glyoxalase I Is Critical for Human Retinal Capillary Pericyte Survival under Hyperglycemic Conditions J. Biol. Chem., April 28, 2006; 281(17): 11864 - 11871. [Abstract] [Full Text] [PDF]

				Y. Takatsume, S. Izawa, and Y. Inoue Methylglyoxal as a Signal Initiator for Activation of the Stress-activated Protein Kinase Cascade in the Fission Yeast Schizosaccharomyces pombe J. Biol. Chem., April 7, 2006; 281(14): 9086 - 9092. [Abstract] [Full Text] [PDF]

				G. T. Wondrak, M. K. Jacobson, and E. L. Jacobson Antimelanoma Activity of Apoptogenic Carbonyl Scavengers J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 805 - 814. [Abstract] [Full Text] [PDF]

				A. Zuin, A. P. Vivancos, M. Sanso, Y. Takatsume, J. Ayte, Y. Inoue, and E. Hidalgo The Glycolytic Metabolite Methylglyoxal Activates Pap1 and Sty1 Stress Responses in Schizosaccharomyces pombe J. Biol. Chem., November 4, 2005; 280(44): 36708 - 36713. [Abstract] [Full Text] [PDF]

				K. Nakajou, S. Horiuchi, M. Sakai, K. Hirata, M. Tanaka, M. Takeya, T. Kai, and M. Otagiri CD36 Is Not Involved in Scavenger Receptor-Mediated Endocytic Uptake of Glycolaldehyde- and Methylglyoxal-Modified Proteins by Liver Endothelial Cells J. Biochem., May 1, 2005; 137(5): 607 - 616. [Abstract] [Full Text] [PDF]

				K. Maeta, S. Izawa, and Y. Inoue Methylglyoxal, a Metabolite Derived from Glycolysis, Functions as a Signal Initiator of the High Osmolarity Glycerol-Mitogen-activated Protein Kinase Cascade and Calcineurin/Crz1-mediated Pathway in Saccharomyces cerevisiae J. Biol. Chem., January 7, 2005; 280(1): 253 - 260. [Abstract] [Full Text] [PDF]

				Y. Wei and M. J. Pagliassotti Hepatospecific effects of fructose on c-jun NH2-terminal kinase: implications for hepatic insulin resistance Am J Physiol Endocrinol Metab, November 1, 2004; 287(5): E926 - E933. [Abstract] [Full Text] [PDF]

				R. De Bont and N. van Larebeke Endogenous DNA damage in humans: a review of quantitative data Mutagenesis, May 1, 2004; 19(3): 169 - 185. [Abstract] [Full Text] [PDF]

				Y. Takagi, J. Du, X.-Y. Ma, I. Nakashima, and F. Nagase Phorbol 12-Myristate 13-Acetate Protects Jurkat Cells from Methylglyoxal-Induced Apoptosis by Preventing c-Jun N-Terminal Kinase-Mediated Leakage of Cytochrome c in an Extracellular Signal-Regulated Kinase-Dependent Manner Mol. Pharmacol., March 1, 2004; 65(3): 778 - 787. [Abstract] [Full Text] [PDF]

				S. R. Salpeter, E. Greyber, G. A. Pasternak, and E. E. Salpeter Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis Arch Intern Med, November 24, 2003; 163(21): 2594 - 2602. [Abstract] [Full Text] [PDF]

				C. A. Haber, T. K. T. Lam, Z. Yu, N. Gupta, T. Goh, E. Bogdanovic, A. Giacca, and I. G. Fantus N-acetylcysteine and taurine prevent hyperglycemia-induced insulin resistance in vivo: possible role of oxidative stress Am J Physiol Endocrinol Metab, October 1, 2003; 285(4): E744 - E753. [Abstract] [Full Text] [PDF]

				M. G. Wulffele, A. Kooy, P. Lehert, D. Bets, J. C. Ogterop, B. Borger van der Burg, A. J.M. Donker, and C. D.A. Stehouwer Combination of Insulin and Metformin in the Treatment of Type 2 Diabetes Diabetes Care, December 1, 2002; 25(12): 2133 - 2140. [Abstract] [Full Text] [PDF]

				C. Severino, P. Brizzi, A. Solinas, G. Secchi, M. Maioli, and G. Tonolo Low-dose dexamethasone in the rat: a model to study insulin resistance Am J Physiol Endocrinol Metab, August 1, 2002; 283(2): E367 - E373. [Abstract] [Full Text] [PDF]

				K. C. Chang, K. S. Paek, H. J. Kim, Y. S. Lee, C. Yabe-Nishimura, and H. G. Seo Substrate-Induced Up-Regulation of Aldose Reductase by Methylglyoxal, a Reactive Oxoaldehyde Elevated in Diabetes Mol. Pharmacol., May 1, 2002; 61(5): 1184 - 1191. [Abstract] [Full Text] [PDF]

				N. N. Chan Improved endothelial function with metformin in type 2 diabetes mellitus J. Am. Coll. Cardiol., December 1, 2001; 38(7): 2131 - 2131. [Full Text] [PDF]

				K. Mather, S. Verma, and T. Anderson Improved endothelial function with metformin in type 2 diabetes mellitus: Reply J. Am. Coll. Cardiol., December 1, 2001; 38(7): 2131 - 2132. [Full Text] [PDF]

				N. Murata-Kamiya and H. Kamiya Methylglyoxal, an endogenous aldehyde, crosslinks DNA polymerase and the substrate DNA Nucleic Acids Res., August 15, 2001; 29(16): 3433 - 3438. [Abstract] [Full Text] [PDF]